MED BIOGENE INC.

598 East Kent Avenue South

Vancouver BC V5X 4V6

NEWS RELEASE

DIRECTORS NOMINATED BY DISSIDENT SHAREHOLDER ELECTED AT ANNUAL GENERAL MEETING

For Immediate Release **September 5, 2014**

VANCOUVER, BC – MED BIOGENE INC. (TSXV: MBI) today announced that, at its Annual and Special General Meeting held on September 5, 2014 in Vancouver, the following four persons were elected as the Directors of the Company: Dr. Iain Weir-Jones, Toby Weir-Jones, David Diebolt and Dr. Terence W. Friedlander, M.D. These persons replace all of the incumbent directors of the Company.

The newly appointed board of directors has appointed the following persons as the officers of the Company in replacement of the existing officers: Dr. Iain Weir-Jones, Chief Executive Officer and Chairman; Ibrahim Ghobrial, Chief Financial Officer.

Dr. Weir-Jones said: "This is an exciting time for MBI and its shareholders. The new management team is anxious to get on with the vital task of building value and restoring faith in the future of the Company in collaboration with our strategic partner, Precision Therapeutics, Inc. We are confident that we are well qualified to do so. We will abide by all of the pledges we have made to the shareholders in our press releases throughout the recent proxy battle. In particular we will strive to conserve the limited financial resources of the Company until the commercial launch of GeneFx Lung. In the near future, the new management team will also be establishing a means of promoting transparency and communications with all shareholders."

Financing

The Company also announced that it has received subscriptions and funds for a non-brokered private placement of $200,000 of units. Each unit will be issued at a price of $0.05 and will consist of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at a price of $0.10 for a period of 24 months. The securities issued pursuant to the private placement will be subject to a four month hold period from the date of closing. The closing of the private placement is conditional upon receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange.

About Med BioGene Inc.

MBI is a life science company based in Vancouver, British Columbia that is currently focused on managing the license and rights to GeneFx Lung. MBI's common shares are listed for trading on the TSX Venture Exchange. For more information, please visit www.medbiogene.com

About GeneFx Lung

GeneFx Lung is a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer (NSCLC) who, following surgical removal of their tumor, are at higher and lower risks of mortality. In an initial study of patient specimens from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial, published in the *Journal of Clinical Oncology*, patients classified by GeneFx Lung as high risk benefited from adjuvant chemotherapy, and those classified as low

risk did not benefit and may have experienced a detrimental effect from adjuvant chemotherapy. In the same study, GeneFx Lung was validated in predicting patient mortality in four independent studies involving data from tumor specimens totaling 375 untreated early-stage NSCLC patients. As published in the *Journal of Thoracic Oncology*, GeneFx Lung was also independently validated in a prospective and blinded manner in predicting patient mortality in a study of 181 specimens from untreated NSCLC patients. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. On April 15, 2011, Precision and MBI closed their commercialization, license and research reimbursement agreement. The commercialization agreement provides to Precision exclusive global rights to develop and commercialize GeneFx Lung.

About Precision Therapeutics, Inc.

Precision Therapeutics, Inc., a leading life science company based in Pittsburgh, Pennsylvania, is dedicated to improving the outcomes of cancer patients by providing personalized medicine solutions that aim to increase quality of life and cancer survival rates. Precision offers a portfolio of products developed to help guide physicians and patients with difficult clinical decisions throughout the continuum of cancer care.

Precision currently markets a number of tests through its CLIA-certified laboratory, including ChemoFx®, BioSpeciFx® and GeneFx® Colon.

For more information on Precision, please visit www.precisiontherapeutics.com.

For corporate information, please contact:

Iain Weir-Jones
Chief Executive Officer
mbi@weir-jones.com

www.medbiogene.com

Certain information in this press release contains forward-looking information and statements ("forward-looking information") of MBI under applicable Canadian and United States legislation. Words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "will," "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but is not limited to, that with respect to the timing, completion and/or results of clinical trials or studies, the timing for commercialization of any products, future profits, future product revenues, future shareholder value, future operations and plans, the completion and use of proceeds from transactions or financings and the prospects for negotiating partnerships or collaborations and their timing. This forward-looking information is only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and is based upon uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speak only as of the date of this press release. MBI's forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking information herein is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any such forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law. Certain information included in this press release in respect of Precision and its scientific, clinical and/ or commercialization efforts and expectations have been provided to MBI by Precision. MBI may not have been able to confirm the accuracy of such information and you should not place undue reliance on any such information, including any information regarding Precision that may constitute forward-looking information. A redacted copy of the commercialization agreement between MBI and Precision may be found at www.sedar.com. Each trademark, trade name or service mark of any entity appearing in this press release belongs to its holder.